BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
Year-over-year operating income growth rate
Latest
779.95%
↑ 186% vs avg
Percentile
P100
Near historical high
Streak
1 qtr
Consecutive growthAccelerating
Average
-908.80%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 779.95% |
| Q3 2025 | -0.65% |
| Q2 2025 | 40.32% |
| Q1 2025 | 570.87% |
| Q4 2024 | -158.61% |
| Q3 2024 | -12.20% |
| Q2 2024 | 160.47% |
| Q1 2024 | 66.05% |
| Q4 2023 | -257.94% |
| Q3 2023 | 42.42% |
| Q2 2023 | 27.14% |
| Q1 2023 | 38.64% |
| Q4 2022 | -165.47% |
| Q3 2022 | 49.76% |
| Q2 2022 | 30.50% |
| Q1 2022 | 4.25% |
| Q4 2021 | -17.03% |
| Q3 2021 | -50.71% |
| Q2 2021 | 42.42% |
| Q1 2021 | 1.96% |
| Q4 2020 | -22.26% |
| Q3 2020 | -11.31% |
| Q2 2020 | 6.02% |
| Q1 2020 | -37494.50% |
| Q4 2019 | 99.69% |
| Q3 2019 | -0.52% |
| Q2 2019 | -19.05% |
| Q1 2019 | -16.10% |
| Q4 2018 | 11.34% |
| Q3 2018 | -56.12% |
| Q2 2018 | 17.84% |
| Q1 2018 | -24.37% |
| Q4 2017 | -33.80% |
| Q3 2017 | 13.97% |
| Q2 2017 | -45.21% |
| Q1 2017 | -30.50% |
| Q4 2016 | 11.39% |
| Q3 2016 | 23.82% |
| Q2 2016 | 36.32% |
| Q1 2016 | -10.78% |